A poll by consulting firm QPharma indicates doctors are in the dark about what needs to be reported and what will be revealed.
Business briefs: Sanofi, GlaxoSmithKline, AllTrials
August 8, 2013
4:24 pm
Sanofi named in China corruption probe; GlaxoSmithKline starts a venture capital fund; and European non-profit AllTrials outlines its transparency goals
Good day, Sunshine: Tools help docs track payments
With a new era of transparency for doctors and life science manufacturers kicking off today, here’s how some organizations are keeping physicians informed.
Companies are moving toward more access to clinical trial data. Despite their new stance, the internal battles haven’t quite ended, some say.
Business briefs: GSK, UCB, AZ, Biogen Idec, CVS, Roche, Forest
July 23, 2013
5:23 pm
China’s industry investigation widens beyond GlaxoSmithKline; PhRMA’s European equivalent rallies patient groups to fight transparency; Biogen Idec says a patient’s death is not linked to Tecfidera; parents swap walk-in clinics for office visit; Roche continues its CEO hunt; and Forest logs 6% sales growth.
Industry pushing for further clarity on Sunshine Act
With a clear buffet exemption in-hand, the agency’s position with respect to CME meals seems pretty clear. Industry is pushing for more clarity around the treatment of accrediting bodies.
Business briefs: GSK and Sanofi, plus state legislative news
June 24, 2013
7:08 pm
GlaxoSmithKline says it is scaling back on acquisitions; Sanofi’s CEO picks a regulatory fight; Maine wants to allow Ex-US meds; and New York State seeks to empower pharmacists.
Business Briefs Merck, GSK, Novo, Walgreen, Epocrates, Doximity
May 9, 2013
2:56 pm
HPV vaccine price cut; Merck files new allergy med with FDA; GSK pursues online transparency; Walgreens ready for greater nurse autonomy; Epocrates ranks high among docs with tablets.
